What is HC Wainwright’s Forecast for LBRX FY2026 Earnings?

LB Pharmaceuticals Inc (NASDAQ:LBRX – Free Report) – Investment analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for shares of LB Pharmaceuticals in a research report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($5.98) per share for the year, down from their previous forecast of ($5.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($6.05) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q4 2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($1.57) EPS, Q2 2027 earnings at ($1.33) EPS, Q3 2027 earnings at ($1.24) EPS, Q4 2027 earnings at ($1.30) EPS and FY2027 earnings at ($5.44) EPS.

LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($1.79) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.18).

Several other equities analysts have also commented on LBRX. Roth Capital lowered shares of LB Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $37.00 to $35.00 in a research report on Monday, October 5th. Piper Sandler reissued an “overweight” rating and set a $78.00 target price on shares of LB Pharmaceuticals in a research report on Monday, August 3rd. Raymond James Financial raised shares of LB Pharmaceuticals to a “buy” rating in a research report on Monday, October 12th. Weiss Ratings restated a “sell (d)” rating on shares of LB Pharmaceuticals in a research note on Wednesday, November 4th. Finally, Stifel Nicolaus set a $53.00 price target on shares of LB Pharmaceuticals in a report on Thursday, August 13th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, LB Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $57.40.

Read Our Latest Report on LB Pharmaceuticals

LB Pharmaceuticals Stock Performance

Shares of LBRX stock opened at $42.46 on Wednesday. LB Pharmaceuticals has a fifty-two week low of $14.40 and a fifty-two week high of $50.16. The stock’s 50-day simple moving average is $40.28 and its 200-day simple moving average is $33.37.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Calamos Advisors LLC purchased a new position in shares of LB Pharmaceuticals in the first quarter worth about $593,000. Profund Advisors LLC purchased a new stake in LB Pharmaceuticals in the third quarter valued at approximately $1,082,000. Sigma Planning Corp purchased a new stake in LB Pharmaceuticals in the third quarter valued at approximately $1,151,000. Great Lakes Advisors LLC purchased a new stake in LB Pharmaceuticals in the second quarter valued at approximately $987,000. Finally, Alps Advisors Inc. increased its holdings in LB Pharmaceuticals by 46.8% in the 3rd quarter. Alps Advisors Inc. now owns 42,732 shares of the company’s stock worth $1,640,000 after buying an additional 13,630 shares during the period.

LB Pharmaceuticals News Summary

These are some of the LBRX news items that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and slightly improved several 2027 EPS forecasts, including its full-year estimate to a loss of $5.44 per share from $5.48. These modest reductions in projected losses are a positive signal. LB Pharmaceuticals coverage
  • Neutral Sentiment: Zacks Research upgraded LBRX from “strong sell” to “hold.” This is an improvement in sentiment, though the new rating remains cautious. Zacks Research ratings
  • Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate to a loss of $5.98 from $5.47, and cut its Q4 2026 and Q1 2027 forecasts. The revisions indicate greater expected losses in the nearer term, tempering the more favorable 2027 changes.

LB Pharmaceuticals Company Profile

(Get Free Report)

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company’s lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.

Recommended Stories

Earnings History and Estimates for LB Pharmaceuticals (NASDAQ:LBRX)

Receive News & Ratings for LB Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LB Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.